Activating rearranged during transfection (RET) mutations function as the initiating causative mutation for
multiple endocrine neoplasia type 2A (
MEN2A). However, no conclusive findings regarding the non-RET genetic events have been reported. This is the first study, to our knowledge, examining genomic alterations in matched MEN2A-associated
tumors. We performed exome sequencing and SNP array analysis of matched
MEN2A tumors and germline
DNA. Somatic alterations were validated in an independent set of patients using Sanger sequencing. Genes of functional interest were further evaluated. The germline RET mutation was found in all MEN2A-component
tumors. Thirty-two somatic mutations were identified in the nine MEN2A-associated
tumors, of which 28 (87.5%) were point mutations and 4 (12.5%) were small insertions, duplications, or deletions. We sequenced all the mutations as well as coding sequence regions of the 12 genes in an independent sample set including 35 medullary
thyroid cancers (20
MEN2A) and 34 PCCs (22
MEN2A), but found no recurrent mutations. Recurrent alterations were found in 13 genes with either mutations or alterations in copy number, including an EIF4G1 mutation (p. E1147V). Mutation of EIF4G1 led to increased cell proliferation and RET/MAPK phosphorylation, while knockdown of EIF4G1 led to reduced cell proliferation and RET/MAPK phosphorylation in TT, MZ-CRC1, and PC-12 cells. We found fewer somatic mutations in endocrine
tumors compared with non-endocrine
tumors. RET was the primary driver in MEN2A-associated
tumors. However, low-frequency alterations such as EIF4G1 might participate in MEN2A-associated
tumorigenesis, possibly by regulating the activity of the RET pathway.